MedTrace Logo

Observational Cohort Study of TachoSil (TC-018-IN)

NCT00285623 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3000

Last updated 2012-05-07

No results posted yet for this study

Summary

The purpose of this study is to collect information, after exposure to TachoSil ®, of all thromboembolic events, immunological events and drug interactions leading to thromboembolic events or major bleeding. In addition, pharmacoeconomic data will be collected.

Conditions

  • Blood Loss, Surgical

Interventions

DRUG

Fibrinogen (human) + thrombin (human) (TachoSil)

treatment in surgery for improvement of haemostasis where standard techniques are insufficient

Sponsors & Collaborators

  • Nycomed

    lead INDUSTRY

Principal Investigators

  • Nycomed Clinical Trial Operations · Headquarters

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-04-30
Completion
2008-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00285623 on ClinicalTrials.gov